TY  - BOOK
AU  - Robbins,Trevor W.
AU  - Sahakian,Barbara J.
ED  - SpringerLink (Online service)
TI  - Translational Neuropsychopharmacology
T2  - Current Topics in Behavioral Neurosciences,
SN  - 9783319339139
AV  - RC321-580 
U1  - 612.8 23
PY  - 2016///
CY  - Cham
PB  - Springer International Publishing, Imprint: Springer
KW  - Medicine
KW  - Neurosciences
KW  - Pharmacology
KW  - Psychopharmacology
KW  - Biomedicine
KW  - Pharmacology/Toxicology
N1  - Translational mouse models of autism; Advancing towards pharmacological therapeutics -- Translatable and back-translatable measurement of impulsivity and compulsivity; convergent and divergent processes -- Translational models of gambling-related decision-making -- Translational research on nicotine dependence -- The need for treatment-responsive translatable biomarkers in alcoholism research -- On the road to translation for PTSD treatment: theoretical and practical considerations of the use of human models of conditioned fear for drug development -- Translational approaches targeting reconsolidation -- Translational assessment of reward and motivational deficits in psychiatric disorders -- Affective biases in humans and animals. Robinson -- Locomotor profiling from the rodents to the clinic and back again -- Animal models of sensori-motor gating in schizophrenia: Are they still relevant? -- Attention and the cholinergic system: relevance to schizophrenia -- Attentional-set-shifting across species -- Relating Translational Neuroimaging and Amperometric Endpoints: Utility for Neuropsychiatric Drug Discovery -- Cognitive translation using the rodent touchscreen test approach -- The Paired Associates Learning (PAL) Test: 30 years of CANTAB Translational Neuroscience From Laboratory to Bedside in Dementia Research -- Translational approaches to experimental medicine
N2  - This book covers wide areas of animal and human psychopharmacology with clinical utility in the treatment of psychiatric and neurological (e.g Alzheimer's disease) disorders. The main theme is to develop a new paradigm for drug discovery that questions the claim that animal models or assays fail adequately to predict Phase 3 clinical trials. A new paradigm is advocated that stresses the importance of intermediate staging points between these extremes that depend on suitable translation of findings from animal studies to Phase 1 or Phase 2 studies utilising experimental medicine
UR  - http://148.231.10.114:2048/login?url=http://dx.doi.org/10.1007/978-3-319-33913-9
ER  -